Back to search

Peptide record

TPDB43029

TG23 Anticancer standard

22 amino acids

3D PDB MODEL

Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

TPDB ID TPDB43029

Peptide_Name

TG23

Activity

Anticancer

Activity_category_statistics

Cancer-related peptides

Database_Source

ACP740 _ACP240 AntiCP 2.0 CancerPPD 2.0 Peptipedia SATPdb iACP-DRLF pep-lab

Sequence_Type

standard

Has_Modification No

Description A 22-aa standard natural anticancer peptide sequence curated from ACP740 _ACP240, AntiCP 2.0, CancerPPD 2.0, and other sources, with an available 3D structural model.

Sequence

TAGIKLTVPIEKFPVTTQTFWG

FASTA

>TPDB43029|Anticancer|length=22
TAGIKLTVPIEKFPVTTQTFWG

Formula C116H180N26O31

Absent Amino Acids RNDCHMSY

Common Amino Acids T

Mass 2434.86

PI 9.88

Basic Residues 2

Acidic Residues 1

Hydrophobic Residues 9

Net Charge +1

Boman Index 0.88

Hydrophobicity 0.245

Aliphatic Index 84.09

Half Life

Mammalian: 7.2 hour Yeast: >20 hour E.coli: >10 hour

Extinction Coefficient Cystines 5500

Absorbance 280nm 225.89

Polar Residues 6

number

Amino Acid Distribution

A: 1 R: 0 N: 0 D: 0 C: 0 E: 1 Q: 1 G: 2 H: 0 I: 2 L: 1 K: 2 M: 0 F: 2 P: 2 S: 0 T: 5 W: 1 Y: 0 V: 2

Length

Formula

C116H180N26O31

Mass

2434.86

9.88

Net Charge

Boman Index

0.88

Hydrophobicity

0.245

C_terminal_Modification

Free

Chirality

Linear_or_Cyclic

Linear

N_terminal_Modification

Free

Nature

Anticancer

Origin

Derived from the SAG1 surface protein from the parasite Toxoplasma gondii

Evidence 1 Activity

Activity

Activity Raw

<5% cytotoxicity at 1 µM

Detail Source Activity Anticancer

Target

Cancer Type Colon Cancer

Cell Line COLO-205

Tissue Affected Colon

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 SATPdb

Source CancerPPD2

Year 2012

Patents WO_2012042540_A2

Other

Source Activity Label	Source Definition
Anticancer	CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.

Evidence 2 Activity

Activity

Activity Raw

~10% cytotoxicity at 10 µM

Detail Source Activity Anticancer

Target

Cancer Type Colon Cancer

Cell Line COLO-205

Tissue Affected Colon

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 SATPdb

Source CancerPPD2

Year 2012

Patents WO_2012042540_A2

Evidence 3 Activity

Activity

Activity Raw

10% cytotoxicity at 1 µM

Detail Source Activity Anticancer

Target

Cancer Type Colon Cancer

Cell Line COLO-205

Tissue Affected Colon

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 SATPdb

Source CancerPPD2

Year 2012

Patents WO_2012042540_A2

Evidence 4 Activity

Activity

Activity Raw

>10% cytotoxicity at 10 µM

Detail Source Activity Anticancer

Target

Cancer Type Colon Cancer

Cell Line COLO-205

Tissue Affected Colon

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 SATPdb

Source CancerPPD2

Year 2012

Patents WO_2012042540_A2

Evidence 5 Activity

Activity

Activity Raw

>10% cytotoxicity at 1 µM

Detail Source Activity Anticancer

Target

Cancer Type Colon Cancer

Cell Line COLO-205

Tissue Affected Colon

Assay & Model

Assay MTT/MTS assay

Testing Time 72-h

Source & Reference

Database Source CancerPPD 2.0 SATPdb

Source CancerPPD2

Year 2012

Patents WO2012042540A2

Evidence 6 Activity

Activity

Activity Raw

<5% cytotoxicity at 10 µM

Detail Source Activity Anticancer

Target

Cancer Type Colon Cancer

Cell Line COLO-205

Tissue Affected Colon

Assay & Model

Assay MTT/MTS assay

Testing Time 72-h

Source & Reference

Database Source CancerPPD 2.0 SATPdb

Source CancerPPD2

Year 2012

Patents WO_2012042540_A2

Evidence 7 Activity

Activity

Activity Raw

~25% cytotoxicity at 1 µM

Detail Source Activity Anticancer

Target

Cancer Type Bladder Cancer

Cell Line UM-UC-3

Tissue Affected Bladder

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 SATPdb

Source CancerPPD2

Year 2012

Patents WO_2012042540_A2

Evidence 8 Activity

Activity

Activity Raw

~25% cytotoxicity at 10 µM

Detail Source Activity Anticancer

Target

Cancer Type Bladder Cancer

Cell Line UM-UC-3

Tissue Affected Bladder

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 SATPdb

Source CancerPPD2

Year 2012

Patents WO_2012042540_A2

Evidence 9 Activity

Activity

Activity Raw

~25% cytotoxicity at 1 µM

Detail Source Activity Anticancer

Target

Cancer Type Bladder Cancer

Cell Line UM-UC-3

Tissue Affected Bladder

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 SATPdb

Source CancerPPD2

Year 2012

Patents WO2012042540A2

Evidence 10 Activity

Activity

Activity Raw

>25% cytotoxicity at 10 µM

Detail Source Activity Anticancer

Target

Cancer Type Bladder Cancer

Cell Line UM-UC-3

Tissue Affected Bladder

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 SATPdb

Source CancerPPD2

Year 2012

Patents WO_2012042540_A2

Evidence 11 Activity

Activity

Activity Raw

~45% cytotoxicity at 1 µM

Detail Source Activity Anticancer

Target

Cancer Type Bladder Cancer

Cell Line UM-UC-3

Tissue Affected Bladder

Assay & Model

Assay MTT/MTS assay

Testing Time 72-h

Source & Reference

Database Source CancerPPD 2.0 SATPdb

Source CancerPPD2

Year 2012

Patents WO_2012042540_A2

Evidence 12 Activity

Activity

Activity Raw

<45% cytotoxicity at 10 µM

Detail Source Activity Anticancer

Target

Cancer Type Bladder Cancer

Cell Line UM-UC-3

Tissue Affected Bladder

Assay & Model

Assay MTT/MTS assay

Testing Time 72-h

Source & Reference

Database Source CancerPPD 2.0 SATPdb

Source CancerPPD2

Year 2012

Patents WO_2012042540_A2

Evidence 13 Activity

Activity

Activity Raw

<15% cytotoxicity at 1 µM

Detail Source Activity Anticancer

Target

Cancer Type Colon Cancer

Cell Line HCT-116

Tissue Affected Colon

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 SATPdb

Source CancerPPD2

Year 2012

Patents WO2012042540A2

Evidence 14 Activity

Activity

Activity Raw

15% cytotoxicity at 10 µM

Detail Source Activity Anticancer

Target

Cancer Type Colon Cancer

Cell Line HCT-116

Tissue Affected Colon

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 SATPdb

Source CancerPPD2

Year 2012

Patents WO_2012042540_A2

Evidence 15 Activity

Activity

Activity Raw

~5% cytotoxicity at 1 µM

Detail Source Activity Anticancer

Target

Cancer Type Colon Cancer

Cell Line HCT-116

Tissue Affected Colon

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 SATPdb

Source CancerPPD2

Year 2012

Patents WO_2012042540_A2

Evidence 16 Activity

Activity

Activity Raw

<5% cytotoxicity at 10 µM

Detail Source Activity Anticancer

Target

Cancer Type Colon Cancer

Cell Line HCT-116

Tissue Affected Colon

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 SATPdb

Source CancerPPD2

Year 2012

Patents WO_2012042540_A2

Evidence 17 Activity

Activity

Activity Raw

<5% cytotoxicity at 1 µM

Detail Source Activity Anticancer

Target

Cancer Type Colon Cancer

Cell Line HCT-116

Tissue Affected Colon

Assay & Model

Assay MTT/MTS assay

Testing Time 72-h

Source & Reference

Database Source CancerPPD 2.0 SATPdb

Source CancerPPD2

Year 2012

Patents WO_2012042540_A2

Evidence 18 Activity

Activity

Activity Raw

<5% cytotoxicity at 10 µM

Detail Source Activity Anticancer

Target

Cancer Type Colon Cancer

Cell Line HCT-116

Tissue Affected Colon

Assay & Model

Assay MTT/MTS assay

Testing Time 72-h

Source & Reference

Database Source CancerPPD 2.0 SATPdb

Source CancerPPD2

Year 2012

Patents WO_2012042540_A2

Evidence 19 Activity

Activity

Activity Raw

5% cytotoxicity at 1 µM

Detail Source Activity Anticancer

Target

Cancer Type Cervical Cancer

Cell Line SiHa

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 SATPdb

Source CancerPPD2

Year 2012

Patents WO_2012042540_A2

Evidence 20 Activity

Activity

Activity Raw

>10% cytotoxicity at 10 µM

Detail Source Activity Anticancer

Target

Cancer Type Cervical Cancer

Cell Line SiHa

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 SATPdb

Source CancerPPD2

Year 2012

Patents WO_2012042540_A2

Evidence 21 Activity

Activity

Activity Raw

<3% cytotoxicity at 1 µM

Detail Source Activity Anticancer

Target

Cancer Type Cervical Cancer

Cell Line SiHa

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 SATPdb

Source CancerPPD2

Year 2012

Patents WO_2012042540_A2

Evidence 22 Activity

Activity

Activity Raw

>20% cytotoxicity at 10 µM

Detail Source Activity Anticancer

Target

Cancer Type Cervical Cancer

Cell Line SiHa

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 SATPdb

Source CancerPPD2

Year 2012

Patents WO_2012042540_A2

Evidence 23 Activity

Activity

Activity Raw

~20% cytotoxicity at 1 µM

Detail Source Activity Anticancer

Target

Cancer Type Cervical Cancer

Cell Line SiHa

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 72-h

Source & Reference

Database Source CancerPPD 2.0 SATPdb

Source CancerPPD2

Year 2012

Patents WO_2012042540_A2

Evidence 24 Activity

Activity

Activity Raw

~40% cytotoxicity at 10 µM

Detail Source Activity Anticancer

Target

Cancer Type Cervical Cancer

Cell Line SiHa

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 72-h

Source & Reference

Database Source CancerPPD 2.0 SATPdb

Source CancerPPD2

Year 2012

Patents WO_2012042540_A2

Evidence 25 Activity

Activity

Activity Raw

~5% cytotoxicity at 1 µM

Detail Source Activity Anticancer

Target

Cancer Type Cervical Cancer

Cell Line CaSki

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 SATPdb

Source CancerPPD2

Year 2012

Patents WO_2012042540_A2

Evidence 26 Activity

Activity

Activity Raw

~15% cytotoxicity at 10 µM

Detail Source Activity Anticancer

Target

Cancer Type Cervical Cancer

Cell Line CaSki

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 SATPdb

Source CancerPPD2

Year 2012

Patents WO_2012042540_A2

Evidence 27 Activity

Activity

Activity Raw

<3% cytotoxicity at 1 µM

Detail Source Activity Anticancer

Target

Cancer Type Cervical Cancer

Cell Line CaSki

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 SATPdb

Source CancerPPD2

Year 2012

Patents WO_2012042540_A2

Evidence 28 Activity

Activity

Activity Raw

>20% cytotoxicity at 10 µM

Detail Source Activity Anticancer

Target

Cancer Type Cervical Cancer

Cell Line CaSki

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 SATPdb

Source CancerPPD2

Year 2012

Patents WO_2012042540_A2

Evidence 29 Activity

Activity

Activity Raw

~15% cytotoxicity at 1 µM

Detail Source Activity Anticancer

Target

Cancer Type Cervical Cancer

Cell Line CaSki

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 72-h

Source & Reference

Database Source CancerPPD 2.0 SATPdb

Source CancerPPD2

Year 2012

Patents WO2012042540A2

Evidence 30 Activity

Activity

Activity Raw

>20% cytotoxicity at 10 µM

Detail Source Activity Anticancer

Target

Cancer Type Cervical Cancer

Cell Line CaSki

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 72-h

Source & Reference

Database Source CancerPPD 2.0 SATPdb

Source CancerPPD2

Year 2012

Patents WO_2012042540_A2

Evidence 31 Activity

Activity

Activity Raw

<15% cytotoxicity at 1 µM

Detail Source Activity Anticancer

Target

Cancer Type Bladder Cancer

Cell Line HTB-9

Tissue Affected Bladder

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 SATPdb

Source CancerPPD2

Year 2012

Patents WO_2012042540_A2

Evidence 32 Activity

Activity

Activity Raw

~15% cytotoxicity at 10 µM

Detail Source Activity Anticancer

Target

Cancer Type Bladder Cancer

Cell Line HTB-9

Tissue Affected Bladder

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 SATPdb

Source CancerPPD2

Year 2012

Patents WO_2012042540_A2

Evidence 33 Activity

Activity

Activity Raw

<5% cytotoxicity at 1 µM

Detail Source Activity Anticancer

Target

Cancer Type Bladder Cancer

Cell Line HTB-9

Tissue Affected Bladder

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 SATPdb

Source CancerPPD2

Year 2012

Patents WO2012042540A2

Evidence 34 Activity

Activity

Activity Raw

<3% cytotoxicity at 10 µM

Detail Source Activity Anticancer

Target

Cancer Type Bladder Cancer

Cell Line HTB-9

Tissue Affected Bladder

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 SATPdb

Source CancerPPD2

Year 2012

Patents WO_2012042540_A2

Evidence 35 Activity

Activity

Activity Raw

<5% cytotoxicity at 1 µM

Detail Source Activity Anticancer

Target

Cancer Type Bladder Cancer

Cell Line HTB-9

Tissue Affected Bladder

Assay & Model

Assay MTT/MTS assay

Testing Time 72-h

Source & Reference

Database Source CancerPPD 2.0 SATPdb

Source CancerPPD2

Year 2012

Patents WO_2012042540_A2

Evidence 36 Activity

Activity

Activity Raw

<5% cytotoxicity at 10 µM

Detail Source Activity Anticancer

Target

Cancer Type Bladder Cancer

Cell Line HTB-9

Tissue Affected Bladder

Assay & Model

Assay MTT/MTS assay

Testing Time 72-h

Source & Reference

Database Source CancerPPD 2.0 SATPdb

Source CancerPPD2

Year 2012

Patents WO_2012042540_A2